Enrolment Period Extended

The study opened for patient enrolment on 6 June 2012, and patients will continue to be enrolled until the target of 1,000 eligible patients is reached (to a maximum of 24 weeks, i.e. up to 21 November 2012). After enrolment patients will be observed for up to 26 weeks.

Examples:

• Patient does not develop IMD:
  Enrolled, observed for 12 weeks.
  Survival assessed at 26 weeks after enrolment.

• Patient does develop IMD:
  Enrolled, observed until IMD is diagnosed.
  Followed for 12 weeks from start of antifungal therapy.
  Survival assessed at 26 weeks after enrolment.